Answers are grounded in this paper and cite their sources.
Magnetic nanoparticle (MNP)-mediated hyperthermia is a promising approach for cancer therapy because it enables the local heating and killing of tumor cells. The systemic administration of MNPs via intravenous injection is crucial for the treatment of a wide range of cancers, including deep-seated tumors. However, the clinical translation of this technology is severely hampered by the extremely low efficiency of nanoparticle delivery to tumor tissues, which has been a major bottleneck limiting therapeutic efficacy. This review provides an overview of recent advances in strategies to overcome this challenge. We first discuss conventional drug delivery system approaches based on the enhanced permeability and retention effect, and then highlight key preclinical studies demonstrating the trend towards developing functional MNPs. Moreover, we explored emerging paradigms, such as the strategic manipulation of nanoparticle-blood protein interactions (protein corona formation) to control the in vivo biodistribution of nanoparticles and the recently proposed active transport and retention principle. Furthermore, we introduce strategies to maximize the local therapeutic efficacy once MNPs reach the tumor, including MNP-based platforms for controlled drug release, subcellular targeting of mitochondria, and the combination of hyperthermia with immunotherapy. The clinical success of magnetic hyperthermia depends on improving nanoparticle delivery to tumors based on a deeper understanding of biological interactions and enhancing the local therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Kaneko et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: